KCNIP3 and Mental deterioration: In addition, treatment with repaglinide has been shown to delay the onset and progression of motor and cognitive decline and extend lifespan by blocking the interaction of KChIP3 and ATF6 [74,159], suggesting that KChIP3 may be a novel target for the treatment of related diseases.